Sarepta’s Duchenne muscular dystrophy drug was approved by the FDA despite a negative recommendation — sparking concerns about setting a precedent.
read more
Sarepta’s Duchenne muscular dystrophy drug was approved by the FDA despite a negative recommendation — sparking concerns about setting a precedent.
read more